Rituximab: gastrointestinal perforation.
D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D002170:Canada; D017024:Chemotherapy, Adjuvant / Q000009:adverse effects; D006801:Humans; D007416:Intestinal Perforation / Q000139:chemically induced*; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy
D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents